PURPOSE: There is mounting evidence that skeletal muscle produces and secretes biologically active proteins or "myokines" that facilitate metabolic cross talk between organ systems. The increased expression of myostatin, a secreted anabolic inhibitor of muscle growth and development, has been associated with obesity and insulin resistance. Despite these intriguing findings, there have been few studies linking myostatin and insulin resistance. METHODS: To explore this relationship in more detail, we quantified myostatin protein in muscle and plasma from 10 insulin-resistant, middle-aged (53.1 ± 5.5 yr) men before and after 6 months of moderate aerobic exercise training (1200 kcal·wk−¹ at 40%-55% VO2peak). To establish a cause-effect relationship, we also injected C57/Bl6 male mice with high physiological levels of recombinant myostatin protein. RESULTS: Myostatin protein levels were shown to decrease in muscle (37%, P = 0.042, n = 10) and matching plasma samples (from 28.7 ng·mL−¹ pretraining to 22.8 ng·mL−¹ posttraining, P = 0.003, n = 9) with aerobic exercise. Furthermore, the strong correlation between plasma myostatin levels and insulin sensitivity (R² = 0.82, P < 0.001, n = 9) suggested a cause-effect relationship that was subsequently confirmed by inducing insulin resistance in myostatin-injected mice. A modest increase (44%) in plasma myostatin levels was also associated with significant reductions in the insulin-stimulated phosphorylation of Akt (Thr308) in both muscle and liver of myostatin-treated animals. CONCLUSIONS: These findings indicate that both muscle and plasma myostatin protein levels are regulated by aerobic exercise and, furthermore, that myostatin is in the causal pathway of acquired insulin resistance with physical inactivity.
PURPOSE: There is mounting evidence that skeletal muscle produces and secretes biologically active proteins or "myokines" that facilitate metabolic cross talk between organ systems. The increased expression of myostatin, a secreted anabolic inhibitor of muscle growth and development, has been associated with obesity and insulin resistance. Despite these intriguing findings, there have been few studies linking myostatin and insulin resistance. METHODS: To explore this relationship in more detail, we quantified myostatin protein in muscle and plasma from 10 insulin-resistant, middle-aged (53.1 ± 5.5 yr) men before and after 6 months of moderate aerobic exercise training (1200 kcal·wk−¹ at 40%-55% VO2peak). To establish a cause-effect relationship, we also injected C57/Bl6 male mice with high physiological levels of recombinant myostatin protein. RESULTS:Myostatin protein levels were shown to decrease in muscle (37%, P = 0.042, n = 10) and matching plasma samples (from 28.7 ng·mL−¹ pretraining to 22.8 ng·mL−¹ posttraining, P = 0.003, n = 9) with aerobic exercise. Furthermore, the strong correlation between plasma myostatin levels and insulin sensitivity (R² = 0.82, P < 0.001, n = 9) suggested a cause-effect relationship that was subsequently confirmed by inducing insulin resistance in myostatin-injected mice. A modest increase (44%) in plasma myostatin levels was also associated with significant reductions in the insulin-stimulated phosphorylation of Akt (Thr308) in both muscle and liver of myostatin-treated animals. CONCLUSIONS: These findings indicate that both muscle and plasma myostatin protein levels are regulated by aerobic exercise and, furthermore, that myostatin is in the causal pathway of acquired insulin resistance with physical inactivity.
Authors: Juha J Hulmi; Vuokko Kovanen; Harri Selänne; William J Kraemer; Keijo Häkkinen; Antti A Mero Journal: Amino Acids Date: 2008-07-27 Impact factor: 3.520
Authors: Juha J Hulmi; Jörgen Tannerstedt; Harri Selänne; Heikki Kainulainen; Vuokko Kovanen; Antti A Mero Journal: J Appl Physiol (1985) Date: 2009-03-19
Authors: Stephen M Roth; Gregory F Martel; Robert E Ferrell; E Jeffrey Metter; Ben F Hurley; Marc A Rogers Journal: Exp Biol Med (Maywood) Date: 2003-06
Authors: Nathan K LeBrasseur; Teresa M Schelhorn; Barbara L Bernardo; Patricia G Cosgrove; Paula M Loria; Thomas A Brown Journal: J Gerontol A Biol Sci Med Sci Date: 2009-05-29 Impact factor: 6.053
Authors: Stéphanie Ricaud; Barbara Vernus; Michel Duclos; Henri Bernardi; Olli Ritvos; Gilles Carnac; Anne Bonnieu Journal: Oncogene Date: 2003-11-13 Impact factor: 9.867
Authors: Michael A Gentile; Pascale V Nantermet; Robert L Vogel; Robert Phillips; Daniel Holder; Paul Hodor; Chun Cheng; Hongyue Dai; Leonard P Freedman; William J Ray Journal: J Mol Endocrinol Date: 2009-09-02 Impact factor: 5.098
Authors: C Zhang; C McFarlane; S Lokireddy; S Bonala; X Ge; S Masuda; P D Gluckman; M Sharma; R Kambadur Journal: Diabetologia Date: 2011-02-24 Impact factor: 10.122